Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma

Por Luke, Jason J., Schwartz, Gary K.
Publicado em 2013

Advances in the Systemic Treatment of Cutaneous Sarcomas

Por Luke, Jason J, Keohan, Mary-Louise
Publicado em 2012

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

Por Luke, Jason J., Hodi, F. Stephen
Publicado em 2013

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

Por Luke, Jason J, Ott, Patrick A
Publicado em 2014

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

Por Luke, Jason J., Ott, Patrick A.
Publicado no Oncotarget (2015)

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a ran...

Por Luke, Jason J., Zha, Yuanyuan, Matijevich, Karen, Gajewski, Thomas F.
Publicado no J Immunother Cancer (2016)

Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer

Por Sweis, Randy F, Spranger, Stefani, Luke, Jason J, Gajewski, Thomas F
Publicado no J Immunother Cancer (2015)

Antitumor Granuloma Formation by CD4(+) T Cells in a Patient With Rapidly Progressive Melanoma Experiencing Spiking Fevers, Neuropathy, and Other Immune-Related Toxicity After Trea...

Por Luke, Jason J., Lezcano, Cecilia, Hodi, F. Stephen, Murphy, George F.
Publicado no J Clin Oncol (2015)

The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors

Por Luke, Jason J, Spranger, Stefani, Bao, Riyue, Andrade, Jorge, Gajewski, Thomas F
Publicado no J Immunother Cancer (2015)

Clinical response of a patient to anti–PD-1 immunotherapy and the immune landscape of testicular germ cell tumors

Por Shah, Shalin, Ward, James E., Bao, Riyue, Hall, Curtis R., Brockstein, Bruce E., Luke, Jason J.
Publicado no Cancer Immunol Res (2016)

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma

Por Luke, Jason J., Donahue, Hilary, Nishino, Mizuki, Giobbie-Hurder, Anita, Davis, Meredith, Bailey, Nancy, Ott, Patrick A., Hodi, F. Stephen
Publicado no Cancer Immunol Res (2015)

Density of immunogenic antigens does not explain presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma

Por Zha, Yuanyuan, Spranger, Stefani, Hernandez, Kyle M, Li, Yan, Bao, Riyue, Alexieff, Peter, Andrade, Jorge, Luke, Jason J, Gajewski, Thomas F
Publicado no J Immunother Cancer (2015)

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

Por Spranger, Stefani, Luke, Jason J., Bao, Riyue, Zha, Yuanyuan, Hernandez, Kyle M., Li, Yan, Gajewski, Alexander P., Andrade, Jorge, Gajewski, Thomas F.
Publicado no Proc Natl Acad Sci U S A (2016)

Systemic high dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study

Por Min, Le, Hodi, F. Stephen, Giobbie-Hurder, Anita, Ott, Patrick A., Luke, Jason J., Donahue, Hilary, Davis, Meredith, Carroll, Rona S., Kaiser, Ursula B.
Publicado no Clin Cancer Res (2014)

ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: Preclinical investigation and a Phase I study in advanced solid tumors

Por Luke, Jason J., LoRusso, Patricia, Shapiro, Geoffrey I., Krivoshik, Andrew, Schuster, Robin, Yamazaki, Takao, Arai, Yukinori, Fakhoury, Allam, Dmuchowski, Carl, Infante, Jeffrey R.
Publicado no Cancer Chemother Pharmacol (2016)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Por Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J.
Publicado no J Immunother Cancer (2016)

The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose escalation clinic...

Por Luke, Jason J., D’Adamo, David R., Dickson, Mark A., Keohan, Mary Louise, Carvajal, Richard D., Maki, Robert G., de Stanchina, Elisa, Musi, Elgilda, Singer, Samuel, Schwartz, Gary K.
Publicado em 2012

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA

Por Oxnard, Geoffrey R., Paweletz, Cloud P., Kuang, Yanan, Mach, Stacy L., O'Connell, Allison, Messineo, Melissa M., Luke, Jason J., Butaney, Mohit, Kirschmeier, Paul, Jackman, David M., Jänne, Pasi A.
Publicado em 2014

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

Por Gangadhar, Tara C, Hamid, Omid, Smith, David C, Bauer, Todd M, Wasser, Jeffrey S, Luke, Jason J, Balmanoukian, Ani S, Kaufman, David R, Zhao, Yufan, Maleski, Janet, Leopold, Lance, Gajewski, Thomas F
Publicado no J Immunother Cancer (2015)

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series

Por Ravi, Sowmya, Spencer, Kristen, Ruisi, Mary, Ibrahim, Nageatte, Luke, Jason J, Thompson, John A, Shirai, Keisuke, Lawson, David, Bartell, Heddy, Kudchadkar, Ragini, Gunter, Ngoc Thi, Mehnert, Janice M, Lipson, Evan J
Publicado em 2014